RU2759669C2 - Фармацевтические комбинации - Google Patents

Фармацевтические комбинации Download PDF

Info

Publication number
RU2759669C2
RU2759669C2 RU2018146812A RU2018146812A RU2759669C2 RU 2759669 C2 RU2759669 C2 RU 2759669C2 RU 2018146812 A RU2018146812 A RU 2018146812A RU 2018146812 A RU2018146812 A RU 2018146812A RU 2759669 C2 RU2759669 C2 RU 2759669C2
Authority
RU
Russia
Prior art keywords
cancer
compound
braf
fluoro
methyl
Prior art date
Application number
RU2018146812A
Other languages
English (en)
Russian (ru)
Other versions
RU2018146812A3 (enExample
RU2018146812A (ru
Inventor
Джордано Капонигро
Чжу Александер Цао
Original Assignee
Аррэй Байофарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2759669(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аррэй Байофарма Инк. filed Critical Аррэй Байофарма Инк.
Publication of RU2018146812A publication Critical patent/RU2018146812A/ru
Publication of RU2018146812A3 publication Critical patent/RU2018146812A3/ru
Application granted granted Critical
Publication of RU2759669C2 publication Critical patent/RU2759669C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2018146812A 2016-06-03 2017-06-02 Фармацевтические комбинации RU2759669C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
US62/345,389 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
RU2018146812A RU2018146812A (ru) 2020-07-09
RU2018146812A3 RU2018146812A3 (enExample) 2020-10-09
RU2759669C2 true RU2759669C2 (ru) 2021-11-16

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018146812A RU2759669C2 (ru) 2016-06-03 2017-06-02 Фармацевтические комбинации

Country Status (26)

Country Link
US (3) US10485788B2 (enExample)
EP (1) EP3463345B1 (enExample)
JP (2) JP6805336B2 (enExample)
KR (1) KR102439911B1 (enExample)
CN (1) CN109890386B (enExample)
AU (1) AU2017275650B2 (enExample)
BR (1) BR112018074941A2 (enExample)
CA (1) CA3026361A1 (enExample)
CL (1) CL2018003421A1 (enExample)
CO (1) CO2019000010A2 (enExample)
CR (1) CR20190002A (enExample)
DK (1) DK3463345T3 (enExample)
FI (1) FI3463345T3 (enExample)
HU (1) HUE060653T2 (enExample)
IL (1) IL263431A (enExample)
MA (1) MA45187A (enExample)
MX (1) MX387795B (enExample)
PH (1) PH12018502549A1 (enExample)
PL (1) PL3463345T3 (enExample)
PT (1) PT3463345T (enExample)
RU (1) RU2759669C2 (enExample)
SG (1) SG11201810793XA (enExample)
SI (1) SI3463345T1 (enExample)
UA (1) UA125436C2 (enExample)
WO (1) WO2017210538A1 (enExample)
ZA (1) ZA201900019B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
JP7676371B2 (ja) 2019-10-11 2025-05-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 薬剤用量決定デバイスおよび方法
EP4103286A4 (en) * 2020-02-10 2024-03-20 Cedars-Sinai Medical Center METHOD OF TREATMENT OF PANCREATIC CANCER
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
JP2025541200A (ja) * 2022-12-15 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2307831C2 (ru) * 2002-03-13 2007-10-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов mek
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
US20150164897A1 (en) * 2012-07-26 2015-06-18 Norvartis Ag Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor
WO2015087279A1 (en) * 2013-12-12 2015-06-18 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
AU2012267888A1 (en) * 2011-06-07 2014-01-30 Caris Mpi, Inc. Molecular profiling for cancer
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
IN2015DN00450A (enExample) * 2012-08-07 2015-06-26 Novartis Ag
CA3079071C (en) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
US9913844B2 (en) 2013-03-21 2018-03-13 Novartis Ag Combination therapy
WO2015008729A1 (ja) 2013-07-18 2015-01-22 株式会社ダイセル 酸化物の製造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
US10323035B2 (en) * 2015-04-01 2019-06-18 Crystal Pharmatech Co., Ltd. Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2307831C2 (ru) * 2002-03-13 2007-10-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов mek
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
US20150164897A1 (en) * 2012-07-26 2015-06-18 Norvartis Ag Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
WO2015087279A1 (en) * 2013-12-12 2015-06-18 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) 26.07.2013. Найдено в Интернет: URL: https://clinicaltrials.gov/ct2/show/record/NCT01909453 (Дата обращения 08.10.2020). *

Also Published As

Publication number Publication date
AU2017275650A1 (en) 2019-01-17
CN109890386B (zh) 2022-05-24
MX387795B (es) 2025-03-19
RU2018146812A3 (enExample) 2020-10-09
PH12018502549A1 (en) 2019-04-08
US11376239B2 (en) 2022-07-05
PL3463345T3 (pl) 2023-02-06
CN109890386A (zh) 2019-06-14
CO2019000010A2 (es) 2019-05-21
RU2018146812A (ru) 2020-07-09
IL263431A (en) 2019-01-31
SI3463345T1 (sl) 2023-02-28
KR102439911B1 (ko) 2022-09-05
DK3463345T3 (da) 2023-01-09
CA3026361A1 (en) 2017-12-07
FI3463345T3 (fi) 2023-01-31
JP6805336B2 (ja) 2020-12-23
BR112018074941A2 (pt) 2019-03-12
EP3463345A1 (en) 2019-04-10
CL2018003421A1 (es) 2019-07-19
UA125436C2 (uk) 2022-03-09
MX2018014973A (es) 2019-12-18
HUE060653T2 (hu) 2023-04-28
US20200230108A1 (en) 2020-07-23
US20190105303A1 (en) 2019-04-11
JP2021054832A (ja) 2021-04-08
MA45187A (fr) 2019-04-10
SG11201810793XA (en) 2018-12-28
KR20190119507A (ko) 2019-10-22
EP3463345B1 (en) 2022-11-02
AU2017275650B2 (en) 2023-06-01
PT3463345T (pt) 2023-01-06
US20230044943A1 (en) 2023-02-09
WO2017210538A1 (en) 2017-12-07
ZA201900019B (en) 2023-04-26
JP2019525948A (ja) 2019-09-12
EP3463345A4 (en) 2020-02-26
US10485788B2 (en) 2019-11-26
CR20190002A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
US20230044943A1 (en) Pharmaceutical Combinations
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2020019780A (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
CN117771363A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
DK2605764T3 (en) Compositions for the treatment of cancer
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
US20230173067A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
JP2021511344A (ja) 癌を治療する組成物および方法
JP2025509278A (ja) 小細胞肺癌を治療する方法
TWI775333B (zh) 治療癌症之方法
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
US20230102483A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
US20190276439A1 (en) Method of treating solid tumors
KR20180129795A (ko) 렌바티닙 및 에베롤리무스를 사용한 신세포 암종의 치료
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
TW202404600A (zh) 使用ptpn11抑制劑及pd-1/pd-l1抑制劑之組合療法
HK40118757A (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant